Janssen 63733657ALZ2002
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer’s Disease.
